IBRX
ImmunityBio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.08
−1.34%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 165.8M | 113.3M | 14.7M | 622.0K | 240.0K |
| Cost of Revenue | 8.9M | 753.0K | — | — | — |
| Gross Profit | 156.9M | 112.5M | 14.7M | 622.0K | 240.0K |
| Operating Expenses | |||||
| R&D Expense | 234.0M | 207.9M | 190.1M | 232.4M | 248.1M |
| SG&A Expense | 165.8M | 147.2M | 168.8M | 129.6M | 102.7M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 8.9M | 13.5M | — | 886.0K | 681.0K |
| Total Operating Expenses | 408.7M | 368.6M | 358.9M | 362.9M | 351.5M |
| Cost and Expenses | 417.6M | 369.3M | 358.9M | 362.9M | 351.5M |
| Operating Income (EBIT) | (251.8M) | (256.0M) | (344.2M) | (362.3M) | (351.3M) |
| Non-Operating | |||||
| Interest Income | 10.8M | 6.7M | 2.4M | 863.0K | 2.7M |
| Interest Expense | 83.3M | 112.5M | 131.7M | 86.7M | 47.1M |
| Net Interest Income | (72.4M) | (105.8M) | (129.3M) | (85.9M) | (44.4M) |
| Other Non-Op Income/Expense | (740.8M) | (95.6M) | (69.5M) | (221.6M) | (66.0M) |
| Non-Operating Income (excl Interest) | 657.5M | (16.9M) | (62.2M) | 134.9M | 18.8M |
| EBT (Pre-Tax Income) | (992.6M) | (351.6M) | (413.6M) | (583.9M) | (417.3M) |
| Income Tax Expense | (179.0K) | (135.0K) | — | (40.0K) | 34.0K |
| Bottom Line | |||||
| Net Income | (992.4M) | (351.4M) | (413.6M) | (583.2M) | (416.6M) |
| Earnings from Cont. Ops | (992.4M) | (351.5M) | (413.6M) | (583.9M) | (417.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (992.4M) | (351.4M) | (413.6M) | (583.2M) | (416.6M) |
| Per Share | |||||
| Basic EPS | ($0.97) | ($0.38) | ($0.59) | ($1.15) | ($1.04) |
| Diluted EPS | ($0.97) | ($0.38) | ($0.62) | ($1.15) | ($1.04) |
| Revenue Per Share | $0.16 | $0.12 | $0.02 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 1.1B | 919.9M | 697.3M | 508.6M | 399.9M |
| Diluted Shares Outstanding | 1.1B | 919.9M | 700.4M | 508.6M | 399.9M |
| Profitability Metrics | |||||
| EBITDA | (888.3M) | (223.6M) | (264.4M) | (478.7M) | (351.9M) |
| D&A | 21.0M | 15.5M | 17.6M | 18.5M | 18.3M |
| EBIT | (909.3M) | (239.1M) | (282.0M) | (497.2M) | (370.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026